Arcutis Biotherapeutics, Inc. (ARQT)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Arcutis Biotherapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Arcutis Biotherapeutics, Inc. (ARQT) has returned -18.87% so far this year and 50.64% over the past 12 months.

Based on dividend-adjusted daily data since Jan 31, 2020, ARQT's average daily return is +0.12%, while the average monthly return is +3.09%. At this rate, your investment would double in approximately 1.9 years.

Historically, 54% of months were positive and 46% were negative. The best month was Jan 2024 with a return of +81.7%, while the worst month was Oct 2023 at -57.6%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 4 months.

On a daily basis, ARQT closed higher 49% of trading days. The best single day was Mar 19, 2020 with a return of +36.4%, while the worst single day was May 10, 2023 at -18.8%.

Arcutis Biotherapeutics, Inc. has an annualized alpha of 18.37%, beta of 1.01, and R² of 0.07 versus S&P 500 Index. Calculated based on daily prices since February 03, 2020.

• This stock participated in 165.96% of S&P 500 Index downside but only 151.80% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.07 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

ARQT ranks 69 for risk / return — better than 69% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for Arcutis Biotherapeutics, Inc. (ARQT) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Arcutis Biotherapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Arcutis Biotherapeutics, Inc. was 95.02%, occurring on Nov 30, 2023. The portfolio has not yet recovered.

The current Arcutis Biotherapeutics, Inc. drawdown is 36.29%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Arcutis Biotherapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Arcutis Biotherapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.